Concordance for myositis-specific autoantibody detection between commercial enzyme-linked immunosorbent assays and line blot assays: a multicentre study conducted across the Asia-Pacific region
Clicks: 1
ID: 317566
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #154 of 202 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 202 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Objectives Laboratory detection of myositis-specific autoantibodies (MSAs) utilises enzyme-linked immunosorbent assays (ELISA) and multianalyte line blot assays (LBA). We sought to evaluate the concordance and reliability of these two commercial assays. Methods Serum samples from patients with idiopathic inflammatory myopathies (IIM) were obtained from 7 countries across the Asia-Pacific region. Anti-Jo-1, anti-EJ, anti-PL-7, anti-PL-12, anti-MDA5, anti-Mi-2, and anti-TIF1-γ antibodies were centrally measured with commercial ELISA and LBA kits. The positive percentage agreement (PPA), negative percentage agreement (NPA), and Cohen’s kappa were calculated by comparing the two assays. Sera with discordant results were subjected to “gold-standard” immunoprecipitation (IP) assays. Results Serum samples obtained from 485 patients with IIMs, including 180 with dermatomyositis, 44 with amyopathic dermatomyositis, 7 with juvenile dermatomyositis, 197 with polymyositis or immune-mediated necrotising myopathy, and 57 with inclusion body myositis, were subjected to ELISA and LBA. The PPA was the highest for anti-Jo-1 at 0.98, followed by 0.94 for anti-PL-7, 0.93 for anti-EJ, 0.93 for anti-MDA5, 0.89 for anti-TIF1-γ, 0.78 for anti-PL-12, and 0.67 for anti-Mi-2, whereas the NPA was high (ranging from 0.97–1 for all MSAs). Kappa values exceeded 0.80 for anti-Jo-1, anti-EJ, anti-MDA5, and anti-TIF1-γ, whereas anti-PL-7, anti-PL-12, and anti-Mi-2 exhibited low values. IP assays using sera with discordant results revealed a high rate of false positives for anti-PL-7 and anti-Mi-2 in LBA. Conclusion Discrepancies in the measurement results were observed between commercially available ELISA and LBA, especially for anti-PL7 and anti-Mi-2. ELISA is more accurate than LBA.
| Reference Key |
openalex_W7164930661
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Takahisa Gono, Vidya Limaye, Latika Gupta, Vikas Agarwal, Ho So, Jasmin Raja, Warren Fong, Suparaporn Wangkaew, Andrea Hsiu Ling Low, Akihiro Murakami, Kimiko Hasegawa, Takuya Isayama, Masataka Kuwana |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag306
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.